.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
SUSTAIN-6 evaluated once-weekly semaglutide in people with type 2 diabetes at high cardiovascular risk. The trial showed a significant reduction in the first occurrence of the composite of cardiovascular death, nonfatal myocardial infarction or nonfatal stroke versus placebo. The results helped move GLP-1 receptor agonists toward an organ-protective role in diabetes care, particularly for patients with established or high cardiovascular risk. For internists, the practical implication is that drug selection should be based on more than HbA1c efficacy. Weight, cardiovascular risk, kidney disease, treatment burden and adverse-effect profile should all be incorporated into shared decisions. The trial was not designed to establish every mechanism behind the benefit, and its population had substantial cardiovascular risk, so extrapolation to very low-risk patients should be cautious. Nevertheless, the findings support a broader model of type 2 diabetes management in which glucose lowering and cardiovascular risk reduction are considered together. It also highlights why early identification of high-risk patients can change the therapeutic pathway even when their HbA1c is not dramatically elevated.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
SUSTAIN-6 evaluated once-weekly semaglutide in people with type 2 diabetes at high cardiovascular risk. The trial showed a significant reduction in the first occurrence of the composite of cardiovascular death, nonfatal myocardial infarction or nonfatal stroke versus placebo. The results helped move GLP-1 receptor agonists toward an organ-protective role in diabetes care, particularly for patients with established or high cardiovascular risk. For internists, the practical implication is that drug selection should be based on more than HbA1c efficacy. Weight, cardiovascular risk, kidney disease, treatment burden and adverse-effect profile should all be incorporated into shared decisions. The trial was not designed to establish every mechanism behind the benefit, and its population had substantial cardiovascular risk, so extrapolation to very low-risk patients should be cautious. Nevertheless, the findings support a broader model of type 2 diabetes management in which glucose lowering and cardiovascular risk reduction are considered together. It also highlights why early identification of high-risk patients can change the therapeutic pathway even when their HbA1c is not dramatically elevated.
4 weeks back
A bioengineered oral nanozyme microsupplement converts pathological ROS into a protective polydopamine hydrogel shield. By curbing neutrophil extracellular traps and balancing T cells, this platform outperforms standard 5-ASA in preclinical colitis models, opening new paths for sustained remission.
3 days back
Recent research reveals that downregulating YAP1/TAZ-TEAD via Hippo signaling triggers spontaneous human trophoblast syncytialization in 3D cultures, illuminating placental biology and preeclampsia.
4 weeks back
Abdominal aortic aneurysm rupture remains a catastrophic vascular emergency. Groundbreaking research reveals that USP53 accelerates aneurysm progression by reprogramming smooth muscle cell metabolism toward aerobic glycolysis, highlighting a promising target beyond conventional diameter-based surveillance.
4 days back
A breakthrough study leverages natural language processing to accurately identify incident medication-related osteonecrosis of the jaw and track antiresorptive drug holidays from clinical narratives in electronic health records, advancing osteoporosis pharmacovigilance and dental safety.
4 days back
Recent research defines ferro-aging as a conserved iron-lipid axis driving organ decline across primates. Age-related iron dyshomeostasis stimulates ACSL4-mediated lipid peroxidation, promoting cellular senescence. Notably, vitamin C directly inhibits ACSL4, suppressing phospholipid oxidation and multi-organ decay.
5 days back
